Summary:
UC is a life-long condition that causes inflammation (pain, swelling) of the colon (part of the bowel or large intestine) due to an over-reaction of the immune system (the body’s defense system, which fights infection). The most common symptoms of UC are diarrhea, abdominal cramps, and rectal bleeding. Rectal bleeding means that blood is coming from the anus either with or without stool. Other symptoms are tiredness and nausea.
The aim of UC therapies is to provide relief from symptoms and reduce inflammation in the lining of the colon (further referred to as “tissue healing”) and improve quality of life. Current treatments include anti-inflammatory medication known as 5-aminosalicylic acid (5-ASA), antibiotics, corticosteroids, and other biologic medications. These medications may help to control the immune system. Available medications may help improve symptoms of UC for some subjects, but not for others. Also, for some subjects, existing treatments may help at first, but the symptoms may return. The study drug is designed to work in a different way than the existing UC therapies.
Criteria:- are at least 18 years old
- have been diagnosed with UC
- did not respond to currently available treatments (UC therapies), responded to UC therapy at first but are no longer responding, or could not tolerate available UC therapies.
Qualified Participants May Receive:
You will be paid $110 per completed visit. If you do not complete the study, you will be paid for the visits completed.